Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core

IF 3.1 3区化学 Q2 CHEMISTRY, APPLIED

Organic Process Research & Development Pub Date : 2024-10-22 DOI:10.1021/acs.oprd.4c0037610.1021/acs.oprd.4c00376

Tomohiro Oki*, Masao Tsukazaki, Junichi Shiina, Hiroshi Fukuda, Minoru Yamawaki, Yasushi Kito, Takenori Ishizawa, Kazutomo Kinoshita, Sosuke Hara, Noriyuki Furuichi, Hatsuo Kawada, Toshiya Ito, Kota Tanaka, Noriaki Maruyama, Daisuke Tamaru, Takahiro Ichige, Masatoshi Koizumi, Yosuke Hosoya, Masahiro Kimura, Mami Yamaguchi, Shigeki Sato, Yuta Miyazaki, Azusa Toya, Hiroshi Iwamura and Kenji Maeda,

{"title":"Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core","authors":"Tomohiro Oki*, Masao Tsukazaki, Junichi Shiina, Hiroshi Fukuda, Minoru Yamawaki, Yasushi Kito, Takenori Ishizawa, Kazutomo Kinoshita, Sosuke Hara, Noriyuki Furuichi, Hatsuo Kawada, Toshiya Ito, Kota Tanaka, Noriaki Maruyama, Daisuke Tamaru, Takahiro Ichige, Masatoshi Koizumi, Yosuke Hosoya, Masahiro Kimura, Mami Yamaguchi, Shigeki Sato, Yuta Miyazaki, Azusa Toya, Hiroshi Iwamura and Kenji Maeda, ","doi":"10.1021/acs.oprd.4c0037610.1021/acs.oprd.4c00376","DOIUrl":null,"url":null,"abstract":"<p >Alectinib (marketed as Alecensa) is an oral, highly potent ALK inhibitor for the treatment of ALK-positive, non–small-cell lung cancer (NSCLC). This paper describes the evolution from a medicinal chemistry synthetic process to a process enabling the scaled-up supply of a high-quality drug substance. A characteristic structural feature of alectinib is its indole-containing tetracyclic core, the construction of which was effectively achieved through intramolecular reductive cyclization and an intramolecular Friedel–Crafts reaction. Furthermore, the optimized synthetic route and conditions were designed to suppress the formation of impurities containing the same tetracyclic scaffold that are difficult to purge in downstream processes. The established manufacturing process could consistently produce alectinib on a multikilogram scale, typically with an overall yield of 29% and purity exceeding 99.9 area%.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"28 11","pages":"4114–4126 4114–4126"},"PeriodicalIF":3.1000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Process Research & Development","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.oprd.4c00376","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}

引用次数: 0

Abstract

Alectinib (marketed as Alecensa) is an oral, highly potent ALK inhibitor for the treatment of ALK-positive, non–small-cell lung cancer (NSCLC). This paper describes the evolution from a medicinal chemistry synthetic process to a process enabling the scaled-up supply of a high-quality drug substance. A characteristic structural feature of alectinib is its indole-containing tetracyclic core, the construction of which was effectively achieved through intramolecular reductive cyclization and an intramolecular Friedel–Crafts reaction. Furthermore, the optimized synthetic route and conditions were designed to suppress the formation of impurities containing the same tetracyclic scaffold that are difficult to purge in downstream processes. The established manufacturing process could consistently produce alectinib on a multikilogram scale, typically with an overall yield of 29% and purity exceeding 99.9 area%.

Abstract Image

查看原文本刊更多论文

开发可扩展的阿来替尼生产工艺，简明制备含吲哚的四环核心化合物

阿来替尼（Alectinib，市场名为 Alecensa）是一种口服高效 ALK 抑制剂，用于治疗 ALK 阳性的非小细胞肺癌 (NSCLC)。本文介绍了从药物化学合成工艺到能够大规模供应高质量药物的工艺的演变过程。阿来替尼的一个结构特征是其含吲哚的四环核心，通过分子内还原环化和分子内弗里德尔-卡夫斯反应有效地构建了这一核心。此外，优化合成路线和条件的目的是抑制在下游工艺中难以清除的含有相同四环支架的杂质的形成。所建立的生产工艺可持续生产多公斤规模的阿来替尼，总产率通常为 29%，纯度超过 99.9%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Organic Process Research & Development 化学-应用化学

CiteScore

6.90

自引率

14.70%

发文量

251

审稿时长

2 months

期刊介绍： The journal Organic Process Research & Development serves as a communication tool between industrial chemists and chemists working in universities and research institutes. As such, it reports original work from the broad field of industrial process chemistry but also presents academic results that are relevant, or potentially relevant, to industrial applications. Process chemistry is the science that enables the safe, environmentally benign and ultimately economical manufacturing of organic compounds that are required in larger amounts to help address the needs of society. Consequently, the Journal encompasses every aspect of organic chemistry, including all aspects of catalysis, synthetic methodology development and synthetic strategy exploration, but also includes aspects from analytical and solid-state chemistry and chemical engineering, such as work-up tools，process safety, or flow-chemistry. The goal of development and optimization of chemical reactions and processes is their transfer to a larger scale; original work describing such studies and the actual implementation on scale is highly relevant to the journal. However, studies on new developments from either industry, research institutes or academia that have not yet been demonstrated on scale, but where an industrial utility can be expected and where the study has addressed important prerequisites for a scale-up and has given confidence into the reliability and practicality of the chemistry, also serve the mission of OPR&D as a communication tool between the different contributors to the field.